Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - XERIS PHARMACEUTICALS INC | a202010-kexhibit322.htm |
| EX-32.1 - EX-32.1 - XERIS PHARMACEUTICALS INC | a202010-kexhibit321.htm |
| EX-31.2 - EX-31.2 - XERIS PHARMACEUTICALS INC | a202010-kexhibit312.htm |
| EX-31.1 - EX-31.1 - XERIS PHARMACEUTICALS INC | a202010-kexhibit311.htm |
| EX-10.36 - EX-10.36 - XERIS PHARMACEUTICALS INC | a202010-kexhibit1036.htm |
| EX-10.34 - EX-10.34 - XERIS PHARMACEUTICALS INC | a202010-kexhibit1034.htm |
| 10-K - 10-K - XERIS PHARMACEUTICALS INC | xers-20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Xeris Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statement (No. 333-233061) on Form S-3 and registration statements (Nos. 333-237120, 333-229587 and 333-225802) on Form S-8 of Xeris Pharmaceuticals, Inc. of our report dated March 9, 2021, with respect to the consolidated balance sheets of Xeris Pharmaceuticals, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two‑year period ended December 31, 2020, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of Xeris Pharmaceuticals, Inc.
/s/ KPMG LLP
Chicago, Illinois
March 9, 2021